智通财经APP获悉，1月13日，强生(JNJ.US)宣布旗下创新治疗药物厄达替尼片 (商品名：博珂)正式获得国家药品监督管理局批准，用于治疗携带易感型FGFR3基因变异，且既往接受至少一线含抗PD-1或抗PD-L1期间或之后出现疾病进展的手术不可切除的局部晚期或转移性尿路上皮癌(UC)成人患者。
强生创新制药中国区总裁Cherry Huang女士表示：“厄达替尼印证了靶向治疗为晚期膀胱癌患者带来的显著获益以及广阔的应用前景，突出了FGFR基因检测在转移性尿路上皮癌诊疗中的重要意义。作为该领域的重要里程碑，此次获批彰显了强生持续推进肿瘤领域精准治疗、改善患者生存获益的长期承诺。未来，我们将继续聚焦于拥有重大未满足医疗需求的领域，以科学领拓医药未来，全力推动肿瘤全生命周期管理，致力于让肿瘤成为一种可控、可治愈的慢性疾病。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.